Treatment · Inherited blindness

EDIT-101 (Brilliance)

The first CRISPR therapy injected directly into a human organ — scientifically encouraging, and discontinued because the eligible population was too small.

Discontinued in vivoeyediscontinuedCEP290

Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

Einfache Erklärung

EDIT-101 was injected under the retina to cut out a faulty piece of a gene causing a severe inherited blindness. Some patients saw meaningfully better. The programme was then stopped — not because it failed, but because so few people in the world have that exact mutation that developing it further did not make commercial sense. It is the clearest example in the field of good science ending for economic reasons.

Tiefer eintauchen

EDIT-101 delivered SpCas9 and dual guides by subretinal AAV5 injection to excise the intronic CEP290 c.2991+1655A>G variant causing Leber congenital amaurosis type 10. The Phase 1/2 BRILLIANCE trial reported clinically meaningful vision improvement in a subset of participants with an acceptable safety profile, published in the New England Journal of Medicine. Editas discontinued development, citing the small eligible population, and subsequently reset its pipeline around in vivo cardiovascular targets.

Sources

New England Journal of Medicine (Pierce et al.) · 2024
Gene editing for CEP290-associated retinal degeneration ↗

Written by The CRISPR Atlas editorial team Last updated Aug 25, 2026

Wichtige Fakten

Company	Editas Medicine
Disease	Leber congenital amaurosis type 10
Technology	CRISPR-Cas9 delivered by AAV5
Delivery	Subretinal injection
Development stage	Discontinued after Phase 1/2
Reason discontinued	Small eligible population — a commercial decision, not a safety finding
Historical significance	First in vivo CRISPR administration to a human organ

Diese Seite zitieren

The CRISPR Atlas. “EDIT-101 (Brilliance).” Updated Aug 25, 2026. https://crisprdecoded.com/treatments/edit-101

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas9

Diseases

Inherited Blindness

Clinical Trials

Single Ascending Dose Study of EDIT-101 in Participants With Leber Congenital Amaurosis Type 10

Genes

CEP290

Companies

Editas Medicine

Nur zu Bildungszwecken Diese Seite ist eine Referenz, keine medizinische Beratung. Forschungs- und Zulassungsstatus können sich ändern; beachten Sie das oben angegebene Aktualisierungsdatum und gleichen Sie wichtige Informationen mit den aufgeführten Primärquellen ab.